US1538678A
(en)
*
|
1923-02-24 |
1925-05-19 |
Joseph S Blinn |
Suppository injector
|
US3791385A
(en)
*
|
1972-10-16 |
1974-02-12 |
A Davis |
Catamenial device and applicator thereof
|
CA1339210C
(en)
|
1988-05-31 |
1997-08-05 |
John Lewicki |
Recombinant techniques for production of novel natriuretic and vasodilator peptides
|
US6406697B1
(en)
|
1989-02-23 |
2002-06-18 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US5225538A
(en)
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
US6541610B1
(en)
|
1989-09-05 |
2003-04-01 |
Immunex Corporation |
Fusion proteins comprising tumor necrosis factor receptor
|
WO1991016342A1
(en)
|
1990-04-20 |
1991-10-31 |
Hisayuki Matsuo |
Novel physiologically active peptide originating in hog
|
JP3026351B2
(en)
|
1990-07-13 |
2000-03-27 |
壽之 松尾 |
Porcine CNP gene and precursor protein
|
JP2930380B2
(en)
|
1990-07-13 |
1999-08-03 |
壽之 松尾 |
New bioactive peptide derived from pig (CNP-53)
|
JP2977158B2
(en)
|
1990-09-07 |
1999-11-10 |
壽之 松尾 |
New bird-derived bioactive peptide (chicken CNP)
|
JP2977159B2
(en)
|
1990-09-07 |
1999-11-10 |
壽之 松尾 |
Frog-derived novel bioactive peptide (frog CNP)
|
JP3026352B2
(en)
|
1990-09-11 |
2000-03-27 |
壽之 松尾 |
Rat CNP cDNA and precursor protein
|
JP3026354B2
(en)
|
1990-09-27 |
2000-03-27 |
壽之 松尾 |
Human CNP gene and precursor protein
|
JP2809533B2
(en)
|
1991-01-31 |
1998-10-08 |
壽之 松尾 |
CNP analog peptide
|
CA2102808A1
(en)
*
|
1991-05-10 |
1992-11-11 |
Hanne Bentz |
Targeted delivery of bone growth factors
|
WO1994020534A1
(en)
|
1993-03-03 |
1994-09-15 |
Mayo Foundation For Medical Education And Research |
Vasonatrin peptide and analogs thereof
|
WO1995005455A1
(en)
*
|
1993-08-13 |
1995-02-23 |
Rijksuniversiteit Te Groningen |
Pharmaceutical composition comprising phosphatase or a derivative thereof
|
ES2194895T3
(en)
|
1993-11-12 |
2003-12-01 |
Genentech Inc |
SPECIAL ATRIAL NATURAL PEPTIDES OF A RECEIVER.
|
US6525022B1
(en)
|
1993-11-12 |
2003-02-25 |
Genentech, Inc. |
Receptor specific atrial natriuretic peptides
|
US5846932A
(en)
|
1993-11-12 |
1998-12-08 |
Genentech, Inc. |
Receptor specific atrial natriuretic peptides
|
US5665704A
(en)
|
1993-11-12 |
1997-09-09 |
Genentech, Inc. |
Receptor specific atrial natriuretic peptides
|
ES2188665T3
(en)
|
1994-06-02 |
2003-07-01 |
Forssmann Wolf Georg |
PROCEDURE FOR THE PREPARATION OF CARDIODYLATIN FRAGMENTS, VERY PURIFIED CARDIODYLATIN FRAGMENTS AND INTERMEDIATE PRODUCTS FOR PREPARATION.
|
JPH0870875A
(en)
|
1994-09-05 |
1996-03-19 |
Tosoh Corp |
Recombined alkali phosphatase-fused protein
|
US5863782A
(en)
|
1995-04-19 |
1999-01-26 |
Women's And Children's Hospital |
Synthetic mammalian sulphamidase and genetic sequences encoding same
|
US6028055A
(en)
|
1996-10-22 |
2000-02-22 |
Genetech, Inc. |
Receptor selective BNP
|
EP0939770A1
(en)
|
1996-10-22 |
1999-09-08 |
Genentech, Inc. |
Receptor specific brain natriuretic peptide (bnp)
|
AU6278298A
(en)
*
|
1997-02-14 |
1998-09-08 |
Salk Institute For Biological Studies, The |
Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
|
JP4394279B2
(en)
|
1998-03-09 |
2010-01-06 |
ジーランド ファーマ アクティーゼルスカブ |
Pharmacologically active peptide conjugates with reduced propensity to enzymatic hydrolysis
|
CA2245903A1
(en)
*
|
1998-09-28 |
2000-03-28 |
Mcgill University |
Use of pex in the treatment of metabolic bone diseases
|
CA2260376A1
(en)
|
1999-02-11 |
2000-08-11 |
Universite De Montreal |
New metalloproteases of the neprilysin family
|
CA2262056A1
(en)
*
|
1999-02-24 |
2000-08-24 |
Guy Boileau |
Composition, methods and reagents for the synthesis of a soluble form of human pex
|
AU2495200A
(en)
|
1999-03-08 |
2000-09-28 |
Genentech Inc. |
Compositions and methods for the treatment of tumor
|
AU772074B2
(en)
|
1999-04-28 |
2004-04-08 |
Vectramed, Inc. |
Enzymatically activated polymeric drug conjugates
|
JP2000327583A
(en)
*
|
1999-05-17 |
2000-11-28 |
Medei Sci Puraningu:Kk |
Bone-directional hormone derivative
|
EP1591453A1
(en)
|
1999-05-17 |
2005-11-02 |
ConjuChem Inc. |
Modified peptides yy and conjugates thereof
|
US6849714B1
(en)
|
1999-05-17 |
2005-02-01 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
US6887470B1
(en)
|
1999-09-10 |
2005-05-03 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
WO2004011498A2
(en)
|
2002-07-31 |
2004-02-05 |
Conjuchem Inc. |
Long lasting natriuretic peptide derivatives
|
US20040266673A1
(en)
|
2002-07-31 |
2004-12-30 |
Peter Bakis |
Long lasting natriuretic peptide derivatives
|
DE19942230C2
(en)
|
1999-09-03 |
2003-09-25 |
Wolf-Georg Forssmann |
Use of natriuretic peptides as antibiotic substances for the treatment of bacterial infections
|
AU1920201A
(en)
|
1999-11-16 |
2001-05-30 |
Genzyme Corporation |
Improved regulatory elements for delivery to the liver
|
US6407211B1
(en)
|
1999-12-17 |
2002-06-18 |
Mayo Foundation For Medical Education And Research |
Chimeric natriuretic peptides
|
AU2583901A
(en)
*
|
1999-12-17 |
2001-06-25 |
Ariad Pharmaceuticals, Inc. |
Proton pump inhibitors
|
JP4237375B2
(en)
|
2000-03-31 |
2009-03-11 |
アスビオファーマ株式会社 |
Pharmaceutical composition used for treatment or prevention of ischemic disease
|
US7678391B2
(en)
|
2000-04-26 |
2010-03-16 |
Queen's University At Kingston |
Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
|
EP1502604A1
(en)
|
2000-04-26 |
2005-02-02 |
Cellegy Pharmaceuticals, Inc |
Use of nitric oxide mimetics in cancer treatment
|
JP2003531179A
(en)
|
2000-04-26 |
2003-10-21 |
クイーンズ ユニバーシティ アット キングストン |
Formulations and methods of using nitric oxide mimetics for malignant cell phenotype
|
US20050142217A1
(en)
|
2000-04-26 |
2005-06-30 |
Adams Michael A. |
Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
|
US6830885B1
(en)
|
2000-08-18 |
2004-12-14 |
Phenogene Therapeutiques Inc. |
Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature
|
DE60123635T2
(en)
|
2000-08-23 |
2007-08-16 |
Enobia Pharma Inc., Montreal |
METHOD AND COMPOSITION FOR PROMOTING OSTEOGENESIS
|
US6436386B1
(en)
*
|
2000-11-14 |
2002-08-20 |
Shearwater Corporation |
Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
|
CA2434237C
(en)
|
2000-12-07 |
2012-05-15 |
Eli Lilly And Company |
Glp-1 fusion proteins
|
JP2002178279A
(en)
|
2000-12-12 |
2002-06-25 |
Ulvac Japan Ltd |
Substrate carrier method
|
AU2002255478A1
(en)
*
|
2001-01-10 |
2002-09-12 |
Pe Corporation (Ny) |
Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
|
JP2002246704A
(en)
|
2001-02-16 |
2002-08-30 |
Philips Japan Ltd |
Electronic device and circuit device
|
IL142118A0
(en)
|
2001-03-20 |
2002-03-10 |
Prochon Biotech Ltd |
Method and composition for treatment of skeletal dysplasias
|
US7888372B2
(en)
|
2001-03-23 |
2011-02-15 |
National Institutes Of Health (Nih) |
Compositions and methods for modulating bone mineral deposition
|
AU2002258592A1
(en)
|
2001-03-23 |
2002-11-25 |
The Burnham Institute |
Compositions and methods for modulating bone mineral deposition
|
ATE437221T1
(en)
|
2001-05-14 |
2009-08-15 |
Gbp Ip Llc |
LENTIVIRAL VECTORS ENCODING CLOTTING FACTORS FOR GENE THERAPY
|
CA2453434C
(en)
|
2001-07-16 |
2009-04-14 |
Hk Pharmaceuticals, Inc. |
Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
|
US6610025B2
(en)
*
|
2001-08-06 |
2003-08-26 |
The Procter & Gamble Company |
Tampon applicator arrangement
|
BRPI0203172B8
(en)
|
2001-09-28 |
2021-05-25 |
Nakao Kazuwa |
pharmaceutical composition for achondroplasia
|
US20050202442A1
(en)
|
2003-12-15 |
2005-09-15 |
Morris David W. |
Novel therapeutic targets in cancer
|
US7425531B2
(en)
|
2001-12-20 |
2008-09-16 |
Enobia Pharma Inc. |
Bone polypeptide-1
|
ES2545090T3
(en)
|
2001-12-21 |
2015-09-08 |
Human Genome Sciences, Inc. |
Albumin and GCSF fusion proteins
|
US20080194481A1
(en)
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
US20030158132A1
(en)
|
2002-01-22 |
2003-08-21 |
Genvec, Inc. |
Method for enhancing bone density or formation
|
EP1492567A1
(en)
|
2002-03-06 |
2005-01-05 |
Cellegy Pharmaceuticals, Inc |
Formulations and methods of using nitric oxide mimetics in cancer treatment
|
WO2003079979A2
(en)
|
2002-03-18 |
2003-10-02 |
Scios Inc. |
Method for treating congestive heart failure
|
US20050113286A1
(en)
|
2002-03-18 |
2005-05-26 |
Schreiner George F. |
Methods for treating congestive heart failure
|
IL149562A0
(en)
|
2002-05-09 |
2002-11-10 |
Prochon Ltd |
Fgf variants and methods for use thereof
|
CA2433479A1
(en)
|
2002-07-22 |
2004-01-22 |
F. Hoffmann-La Roche Ag |
Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
|
AU2003270427A1
(en)
|
2002-09-06 |
2004-03-29 |
University Of South Florida |
Cellular delivery of natriuretic peptides
|
AU2003302087A1
(en)
|
2002-11-18 |
2004-06-15 |
Syn X Pharma, Inc. |
Polyclonal-monoclonal elisa assay for detecting n-terminus probnp
|
US7648962B2
(en)
|
2002-11-26 |
2010-01-19 |
Biocon Limited |
Natriuretic compounds, conjugates, and uses thereof
|
AU2003297583B2
(en)
|
2002-11-26 |
2010-01-14 |
Biocon, Ltd |
Modified naturetic compounds, conjugates, and uses thereof
|
US7105539B2
(en)
|
2002-12-03 |
2006-09-12 |
Enobia Pharma |
Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex
|
EP1583554A2
(en)
|
2003-01-13 |
2005-10-12 |
Gudrun Rappold-Hoerbrand |
Use of natriuretic peptides for the treatment of stature disorders related to the shox gene
|
JP2009520459A
(en)
|
2003-02-14 |
2009-05-28 |
サイグレス ディスカバリー, インコーポレイテッド |
Therapeutic target in cancer
|
US7488713B2
(en)
|
2004-03-18 |
2009-02-10 |
University Of South Florida |
Cancer treatment using C-type natriuretic peptides
|
JP2006527190A
(en)
|
2003-04-17 |
2006-11-30 |
サイファージェン バイオシステムズ インコーポレイテッド |
Polypeptides related to natriuretic peptides and their identification and use
|
AU2004257142A1
(en)
|
2003-05-30 |
2005-01-27 |
Alexion Pharmaceuticals, Inc. |
Antibodies and fusion proteins that include engineered constant regions
|
DK1644740T3
(en)
|
2003-06-17 |
2011-02-21 |
Otago Innovation Ltd |
Assessment of skeletal growth using measurements of NT-CNP peptides
|
US8354496B2
(en)
|
2003-06-20 |
2013-01-15 |
Mayo Foundation For Medical Education And Research |
Isoforms of brain natriuretic peptide
|
WO2005052593A1
(en)
|
2003-10-29 |
2005-06-09 |
The University Of Leicester |
Detection
|
US7431915B2
(en)
|
2003-10-31 |
2008-10-07 |
The Regents Of The University Of California |
Peptides whose uptake by cells is controllable
|
US8110665B2
(en)
|
2003-11-13 |
2012-02-07 |
Hanmi Holdings Co., Ltd. |
Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
|
KR20050047030A
(en)
|
2003-11-13 |
2005-05-19 |
한미약품 주식회사 |
Igg fc fragment for a drug carrier and method for the preparation thereof
|
WO2005070446A1
(en)
|
2004-01-15 |
2005-08-04 |
Scios Inc. |
Method for treating cardiac remodeling following myocardial injury
|
US20080182299A1
(en)
|
2004-01-27 |
2008-07-31 |
Compugent Ltd. |
Novel brain natriuretic peptide variants and methods of use thereof
|
CA2554599A1
(en)
|
2004-01-27 |
2005-08-11 |
Compugen Usa, Inc. |
Novel brain natriuretic peptide variants and methods of use thereof
|
JP4972403B2
(en)
|
2004-03-31 |
2012-07-11 |
一和 中尾 |
Height-enhancing composition
|
CN1960758B
(en)
|
2004-03-31 |
2014-10-22 |
中外制药株式会社 |
Remedy or preventive for arthritis
|
JP2005292718A
(en)
|
2004-04-05 |
2005-10-20 |
Furukawa Electric Co Ltd:The |
Optical waveguide, optical waveguide module, and method of fabricating optical waveguide
|
EP2348114B1
(en)
|
2004-04-21 |
2018-07-25 |
Alexion Pharmaceuticals, Inc. |
Bone delivery conjugates and method of using same to target proteins to bone
|
WO2005110435A1
(en)
|
2004-05-10 |
2005-11-24 |
Novacea, Inc. |
Prevention of arterial restenosis with active vitamin d compounds
|
US7972593B2
(en)
|
2004-06-10 |
2011-07-05 |
Saint Louis University |
Delivery of therapeutic agents to the bone
|
US20070081984A1
(en)
*
|
2005-10-11 |
2007-04-12 |
Shunji Tomatsu |
Compositions and methods for treating hypophosphatasia
|
US7863238B2
(en)
*
|
2004-06-10 |
2011-01-04 |
Saint Louis University |
Proteins with an attached short peptide of acidic amino acids
|
US20070081986A1
(en)
*
|
2005-10-07 |
2007-04-12 |
Shunji Tomatsu |
Beta-glucuronidase with an attached short peptide of acidic amino acids
|
WO2006005140A2
(en)
|
2004-07-15 |
2006-01-19 |
The University Of Queensland |
Proteinaceous compounds and uses therefor
|
WO2006039480A2
(en)
|
2004-09-29 |
2006-04-13 |
The Burnham Institute For Medical Research |
Tissue non-specific alkaline phosphate (tnap): a therapeutic target for arterial calcification
|
MX2007006524A
(en)
|
2004-12-01 |
2007-06-22 |
Genzyme Corp |
Methods for targeted delivery of genetic material to the liver.
|
DK1865976T3
(en)
|
2005-04-07 |
2012-07-23 |
Cardiopep Pharma Gmbh |
Use of natriuretic peptides for the treatment of heart failure
|
AU2006239851B2
(en)
|
2005-04-26 |
2011-06-16 |
Medimmune, Llc |
Modulation of antibody effector function by hinge domain engineering
|
US20070042957A1
(en)
|
2005-08-19 |
2007-02-22 |
Mayo Foundation For Medical Education And Research |
Type v phosphodiesterase inhibitors and natriuretic polypeptides
|
US7470668B2
(en)
|
2005-08-24 |
2008-12-30 |
Enobia Pharma Inc. |
Method of use of specific natriuretic peptide receptor c ligands, transgenic non-human mammals expressing specific natriuretic peptide receptor c antagonists and cells thereof
|
AU2006343306A1
(en)
|
2005-09-06 |
2007-11-15 |
Zelos Therapeutics, Inc. |
Parathyroid hormone analogues and methods of use
|
US7803901B2
(en)
|
2005-09-16 |
2010-09-28 |
Mayo Foundation For Medical Education And Research |
Polypeptides with natriuresis activity
|
WO2007041645A2
(en)
|
2005-10-03 |
2007-04-12 |
Scios Inc. |
Oxidized human bnp
|
RU2316334C2
(en)
|
2005-12-19 |
2008-02-10 |
Медитек Индастриз ЛЛС |
Method for activating lost motor functions and determining their recovery effectiveness in central nervous system injury cases
|
US7625564B2
(en)
|
2006-01-27 |
2009-12-01 |
Novagen Holding Corporation |
Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
|
WO2007097923A2
(en)
|
2006-02-20 |
2007-08-30 |
Phylogica Limited |
Method of constructing and screening libraries of peptide structures
|
US8784833B2
(en)
|
2006-06-27 |
2014-07-22 |
Saint Louis University |
Prenatal enzyme replacement therapy for hypophosphatasia
|
JP2010501026A
(en)
|
2006-06-30 |
2010-01-14 |
インターフェース バイオロジクス,インコーポレーテッド |
Bioresponsive polymer
|
BRPI0716416A2
(en)
|
2006-08-08 |
2016-10-11 |
Mayo Foundation |
substantially pure polypeptide between 37 and 47 amino acid in length, isolated nucleic acid, vector: host cell and pharmaceutical composition
|
US7825092B2
(en)
|
2006-08-08 |
2010-11-02 |
University Of South Florida |
Dendroaspis natriuretic peptide for treatment of cancer
|
JP5840345B2
(en)
|
2006-09-08 |
2016-01-06 |
アンブルックス, インコーポレイテッドAmbrx, Inc. |
Modified human plasma polypeptides or modified human Fc scaffold proteins and uses thereof
|
US8283318B2
(en)
|
2006-09-08 |
2012-10-09 |
Mayo Foundation For Medical Education And Research |
Aquaretic and natriuretic polypeptides lacking vasodilatory activity
|
AR063384A1
(en)
|
2006-10-25 |
2009-01-28 |
Amgen Inc |
THERAPEUTIC AGENTS BASED ON PEPTIDES DERIVED FROM TOXINS
|
WO2008058016A2
(en)
|
2006-11-02 |
2008-05-15 |
University Of Virginia Patent Foundation |
Ethoid-containing compounds, methods for preparing ethoid-containing compounds, and methods for use
|
WO2008067199A2
(en)
|
2006-11-16 |
2008-06-05 |
Kai Pharmaceuticals, Inc. |
Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
|
US20080181903A1
(en)
|
2006-12-21 |
2008-07-31 |
Pdl Biopharma, Inc. |
Conjugate of natriuretic peptide and antibody constant region
|
CA2680537C
(en)
|
2007-03-12 |
2018-10-16 |
Soheyl Bahrami |
Diagnosis of septic complications
|
EP1985697A1
(en)
|
2007-04-27 |
2008-10-29 |
AM-Pharma B.V. |
Modified phosphatases
|
KR20080098216A
(en)
|
2007-05-04 |
2008-11-07 |
한미약품 주식회사 |
Natriuretic peptide conjugate using carrier substance
|
ATE536413T1
(en)
|
2007-05-11 |
2011-12-15 |
Enobia Pharma Inc |
BONE TARGETED ALKALINE PHOSPHATASE, KITS AND METHODS OF USE THEREOF
|
CA2687117A1
(en)
|
2007-05-14 |
2008-11-27 |
Biogen Idec Ma Inc. |
Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
|
EP2162464A1
(en)
|
2007-06-06 |
2010-03-17 |
Boehringer Ingelheim International GmbH |
Natriuretic fusion proteins
|
US8999337B2
(en)
|
2007-06-11 |
2015-04-07 |
Abbvie Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
|
US20110077383A1
(en)
|
2007-07-03 |
2011-03-31 |
Medimmune, Llc |
Hinge domain engineering
|
WO2009006732A1
(en)
|
2007-07-06 |
2009-01-15 |
Theratechnologies Inc. |
Bifunctional fusion proteins of the alpha-melanocyte stimulating hormone (alpha-msh) and atrial natriuretic protein (anp) and uses in hypertension and acute kidney injury
|
EP2765139B1
(en)
|
2007-07-20 |
2017-04-12 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides
|
CA2696113A1
(en)
|
2007-08-10 |
2009-04-02 |
Burnham Institute For Medical Research |
Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof
|
EP2185701A4
(en)
|
2007-08-15 |
2011-03-02 |
Amunix Operating Inc |
Compositions and methods for modifying properties of biologically active polypeptides
|
JP5395794B2
(en)
|
2007-09-11 |
2014-01-22 |
モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト |
Use of galanin peptides as therapeutic agents
|
WO2009039981A2
(en)
|
2007-09-11 |
2009-04-02 |
Mondobiotech Laboratories Ag |
Use of a peptide as a therapeutic agent
|
WO2009039985A2
(en)
|
2007-09-11 |
2009-04-02 |
Mondobiotech Laboratories Ag |
Therapeutic uses of urocortin ii
|
AU2008306255A1
(en)
|
2007-09-11 |
2009-04-09 |
Mondobiotech Laboratories Ag |
Use of neurotrophic factor for retinal cholinergic neruons (NFRCN) and chorionic gonadotropin-beta (109-145) as therapeutic agents
|
KR20100063716A
(en)
|
2007-09-11 |
2010-06-11 |
몬도바이오테크 래보래토리즈 아게 |
Astressin and beta-endorphin for use as therapeutic agents
|
US8293711B2
(en)
|
2007-09-11 |
2012-10-23 |
Pharis Biotech Gmbh |
Use of natriuretic peptides for treating angioedema syndromes
|
WO2009036448A2
(en)
|
2007-09-15 |
2009-03-19 |
Mayo Foundation For Medical Education And Research |
Natriuretic peptide receptor-c agonists
|
JP2011504506A
(en)
|
2007-11-21 |
2011-02-10 |
バイオマリン ファーマシューティカル インコーポレイテッド |
Variant of C-type natriuretic peptide
|
WO2009086126A2
(en)
|
2007-12-21 |
2009-07-09 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides
|
EP2080812A1
(en)
|
2008-01-18 |
2009-07-22 |
Transmedi SA |
Compositions and methods of detecting post-stop peptides
|
CN101809029B
(en)
|
2008-05-23 |
2016-06-15 |
第一三共株式会社 |
There is the peptide of the plasma half-life effect extending target peptide
|
WO2009149161A2
(en)
|
2008-06-06 |
2009-12-10 |
Mayo Foundation For Medical Education And Research |
Chimeric natriuretic polypeptides and methods for inhibiting cardiac remodeling
|
WO2009156481A1
(en)
|
2008-06-25 |
2009-12-30 |
Ascendis Pharma As |
Pegylated bnp
|
CA2729096C
(en)
|
2008-06-26 |
2020-04-28 |
Acceleron Pharma Inc. |
Methods for dosing an actriib antagonist and monitoring of treated patients
|
US8741842B2
(en)
|
2008-07-02 |
2014-06-03 |
Mayo Foundation For Medical Education And Research |
Chimeric natriuretic polypeptides with unique pharmacologic profiles
|
TWI388570B
(en)
|
2008-07-23 |
2013-03-11 |
Hanmi Science Co Ltd |
A polypeptide complex comprising non-peptidyl polymer having three functional ends
|
US20100093678A1
(en)
|
2008-10-10 |
2010-04-15 |
The University Of Georgia Research Foundation, Inc |
Compositions and methods of the treatment of obesity and osteoporosis
|
WO2010048308A2
(en)
|
2008-10-24 |
2010-04-29 |
Deborah Dickey |
Natriuretic polypeptides
|
WO2010078325A2
(en)
|
2008-12-29 |
2010-07-08 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides for reducing or preventing restenosis
|
KR20100084996A
(en)
|
2009-01-19 |
2010-07-28 |
한미홀딩스 주식회사 |
Method for producing physiologically active protein or peptide using immunoglobulin fragment
|
JP2012521784A
(en)
|
2009-03-30 |
2012-09-20 |
ベーリンガー・インゲルハイム・インテルナツィオナール・ゲーエムバーハー |
Fusion protein containing canine Fc portion
|
WO2010129655A2
(en)
|
2009-05-05 |
2010-11-11 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides having mutations within their disulfide rings
|
EP3175863B1
(en)
|
2009-05-20 |
2021-12-01 |
BioMarin Pharmaceutical Inc. |
Variants of c-type natriuretic peptide
|
KR20130118203A
(en)
|
2010-04-30 |
2013-10-29 |
알렉시온 파마 인터내셔널 에스에이알엘 |
Methods, compositions, and kits for the treatment of matrix mineralization disorders
|
CA2823066A1
(en)
|
2010-12-27 |
2012-07-05 |
Alexion Pharma International Sarl |
Compositions comprising natriuretic peptides and methods of use thereof
|
SG11201401605QA
(en)
|
2011-10-19 |
2014-09-26 |
Alexion Pharma Holding |
Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
|
WO2013071262A1
(en)
|
2011-11-10 |
2013-05-16 |
Kai Pharmaceuticals, Inc. |
Calcimimetics and methods for their use
|
US10052366B2
(en)
|
2012-05-21 |
2018-08-21 |
Alexion Pharmaceuticsl, Inc. |
Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
|
JP2015526423A
(en)
|
2012-07-25 |
2015-09-10 |
サイオクサス セラピューティクス リミテッド |
Use of S-pindolol to treat cachexia and sarcopenia
|
ES2688066T3
(en)
|
2014-01-24 |
2018-10-30 |
Am-Pharma B.V. |
Processing for recovery and purification of an alkaline phosphatase
|
JP6808493B2
(en)
|
2014-06-09 |
2021-01-06 |
ウルトラジェニクス ファーマシューティカル インク.Ultragenyx Pharmaceutical Inc. |
Effective and efficient control of serum phosphorus for optimal bone formation
|
US10822596B2
(en)
|
2014-07-11 |
2020-11-03 |
Alexion Pharmaceuticals, Inc. |
Compositions and methods for treating craniosynostosis
|
EP3226891A1
(en)
|
2014-12-05 |
2017-10-11 |
Alexion Pharmaceuticals, Inc. |
Treating seizure with recombinant alkaline phosphatase
|
US10603361B2
(en)
|
2015-01-28 |
2020-03-31 |
Alexion Pharmaceuticals, Inc. |
Methods of treating a subject with an alkaline phosphatase deficiency
|
US11352612B2
(en)
|
2015-08-17 |
2022-06-07 |
Alexion Pharmaceuticals, Inc. |
Manufacturing of alkaline phosphatases
|
JP6868617B2
(en)
|
2015-09-28 |
2021-05-12 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
Identifying effective dosing regimens for tissue-nonspecific alkaline phosphatase (TNSALP) enzyme replacement therapy for hypophosphataseemia
|
JP2018533571A
(en)
|
2015-10-30 |
2018-11-15 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
Methods for treating cranial suture early healing disease in a patient
|
EP3426286A4
(en)
|
2016-03-08 |
2019-12-04 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in children
|
WO2017173395A1
(en)
|
2016-04-01 |
2017-10-05 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in adolescents and adults
|
US11186832B2
(en)
|
2016-04-01 |
2021-11-30 |
Alexion Pharmaceuticals, Inc. |
Treating muscle weakness with alkaline phosphatases
|
WO2017171871A1
(en)
|
2016-04-01 |
2017-10-05 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in adolescents and adults
|
US10988744B2
(en)
|
2016-06-06 |
2021-04-27 |
Alexion Pharmaceuticals, Inc. |
Method of producing alkaline phosphatase
|
ES2887573T3
(en)
|
2016-06-27 |
2021-12-23 |
Alexion Pharma Inc |
Methods for treating hypophosphatasia in children and adolescents
|
US11116821B2
(en)
|
2016-08-18 |
2021-09-14 |
Alexion Pharmaceuticals, Inc. |
Methods for treating tracheobronchomalacia
|